Zoetis Inc
ZTS127.170USD
+0.320+0.25%
Cierre 01/09, 16:00（ET）Cotizaciones retrasadas 15 min
56.14BCap. mercado
21.41P/E TTM
Más Datos de Zoetis Inc Compañía
Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).
Información de Zoetis Inc
Símbolo de cotizaciónZTS
Nombre de la empresaZoetis Inc
Fecha de salida a bolsaFeb 01, 2013
Director ejecutivoPeck (Kristin C)
Número de empleados13800
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 01
Dirección10 Sylvan Way
CiudadPARSIPPANY
Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE
PaísUnited States of America
Código postal07054
Teléfono19738227000
Sitio Webhttps://www.zoetis.com/
Símbolo de cotizaciónZTS
Fecha de salida a bolsaFeb 01, 2013
Director ejecutivoPeck (Kristin C)
Ejecutivos de Zoetis Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Kristin C. Peck
Ms. Kristin C. Peck
Chief Executive Officer, Director
Chief Executive Officer, Director
95.01K
+18.00%
Mr. Gregory (Greg) Norden
Mr. Gregory (Greg) Norden
Independent Director
Independent Director
16.95K
+1843.00%
Ms. Louise M. Parent
Ms. Louise M. Parent
Independent Director
Independent Director
15.26K
--
Mr. Sanjay Khosla
Mr. Sanjay Khosla
Independent Director
Independent Director
9.81K
--
Dr. Robert J. (Rob) Polzer, Ph.D.
Dr. Robert J. (Rob) Polzer, Ph.D.
Executive Vice President, President - Research and Development
Executive Vice President, President - Research and Development
6.19K
+24.00%
Ms. Rimma Driscoll
Ms. Rimma Driscoll
Executive Vice President and Head of Global Strategy, Commercial and Business Development, and Global BioDevices
Executive Vice President and Head of Global Strategy, Commercial and Business Development, and Global BioDevices
5.19K
+397.00%
Ms. Vanessa Broadhurst
Ms. Vanessa Broadhurst
Independent Director
Independent Director
2.82K
+961.00%
Mr. Jamie Brannan
Mr. Jamie Brannan
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
2.59K
+418.00%
Mr. Keith Sarbaugh
Mr. Keith Sarbaugh
Executive Vice President, Chief Digital and Technology Officer
Executive Vice President, Chief Digital and Technology Officer
2.04K
+990.00%
Mr. Nicholas (Nick) Ashton
Mr. Nicholas (Nick) Ashton
Executive Vice President, President - Global Manufacturing and Supply
Executive Vice President, President - Global Manufacturing and Supply
1.09K
+448.00%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Kristin C. Peck
Ms. Kristin C. Peck
Chief Executive Officer, Director
Chief Executive Officer, Director
95.01K
+18.00%
Mr. Gregory (Greg) Norden
Mr. Gregory (Greg) Norden
Independent Director
Independent Director
16.95K
+1843.00%
Ms. Louise M. Parent
Ms. Louise M. Parent
Independent Director
Independent Director
15.26K
--
Mr. Sanjay Khosla
Mr. Sanjay Khosla
Independent Director
Independent Director
9.81K
--
Dr. Robert J. (Rob) Polzer, Ph.D.
Dr. Robert J. (Rob) Polzer, Ph.D.
Executive Vice President, President - Research and Development
Executive Vice President, President - Research and Development
6.19K
+24.00%
Ms. Rimma Driscoll
Ms. Rimma Driscoll
Executive Vice President and Head of Global Strategy, Commercial and Business Development, and Global BioDevices
Executive Vice President and Head of Global Strategy, Commercial and Business Development, and Global BioDevices
5.19K
+397.00%
Desglose de ingresos
Divisa: USDActualizado: mar., 6 de ene
Divisa: USDActualizado: mar., 6 de ene
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
Parasiticides
564.00M
23.50%
Vaccines
496.00M
20.67%
Dermatology
472.00M
19.67%
Anti-infectives
284.00M
11.83%
Pain and sedation
204.00M
8.50%
Otro
380.00M
15.83%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
1.32B
55.08%
Other emerging markets
228.00M
9.50%
Other Developed
164.00M
6.83%
Brazil
100.00M
4.17%
Australia
87.00M
3.62%
Otro
499.00M
20.79%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Parasiticides
564.00M
23.50%
Vaccines
496.00M
20.67%
Dermatology
472.00M
19.67%
Anti-infectives
284.00M
11.83%
Pain and sedation
204.00M
8.50%
Otro
380.00M
15.83%
Estadísticas de accionistas
Actualizado: sáb., 10 de ene
Actualizado: sáb., 10 de ene
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
10.84%
BlackRock Institutional Trust Company, N.A.
5.17%
State Street Investment Management (US)
4.46%
State Farm Insurance Companies
3.83%
Geode Capital Management, L.L.C.
2.53%
Otro
73.17%
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
10.84%
BlackRock Institutional Trust Company, N.A.
5.17%
State Street Investment Management (US)
4.46%
State Farm Insurance Companies
3.83%
Geode Capital Management, L.L.C.
2.53%
Otro
73.17%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
49.16%
Investment Advisor/Hedge Fund
32.07%
Research Firm
4.42%
Insurance Company
3.92%
Bank and Trust
2.63%
Pension Fund
2.55%
Hedge Fund
1.56%
Sovereign Wealth Fund
1.25%
Family Office
0.15%
Otro
2.30%
Participación institucional
Actualizado: jue., 1 de ene
Actualizado: jue., 1 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
3273
437.10M
99.18%
-8.45M
2025Q3
3275
435.62M
98.29%
-1.39M
2025Q2
3277
434.35M
98.00%
-1.58M
2025Q1
3284
432.42M
97.12%
-4.21M
2024Q4
3199
430.60M
96.14%
-9.58M
2024Q3
3090
434.14M
95.81%
-13.19M
2024Q2
3062
437.75M
95.94%
-9.33M
2024Q1
3060
439.45M
96.16%
-2.63M
2023Q4
3074
438.13M
95.43%
-2.08M
2023Q3
2966
434.04M
94.28%
-3.00M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
The Vanguard Group, Inc.
47.78M
10.84%
+5.68M
+13.48%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
22.80M
5.17%
+144.71K
+0.64%
Sep 30, 2025
State Street Investment Management (US)
19.65M
4.46%
-89.97K
-0.46%
Sep 30, 2025
State Farm Insurance Companies
16.87M
3.83%
+21.40K
+0.13%
Sep 30, 2025
Geode Capital Management, L.L.C.
11.14M
2.53%
+57.14K
+0.52%
Sep 30, 2025
Wellington Management Company, LLP
8.54M
1.94%
-348.26K
-3.92%
Sep 30, 2025
Polen Capital Management, LLC
7.52M
1.71%
-904.12K
-10.74%
Sep 30, 2025
Morgan Stanley Investment Management Ltd. (UK)
7.48M
1.7%
+722.07K
+10.69%
Sep 30, 2025
Wells Fargo Advisors
5.64M
1.28%
-193.47K
-3.32%
Sep 30, 2025
Norges Bank Investment Management (NBIM)
5.19M
1.18%
+131.36K
+2.60%
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
ProShares Pet Care ETF
9.4%
VanEck Pharmaceutical ETF
9.02%
VanEck Agribusiness ETF
7.81%
iShares U.S. Pharmaceuticals ETF
4.26%
Honeytree US Equity ETF
3.86%
First Trust NASDAQ Pharmaceuticals ETF
3.58%
Polen Capital Global Growth ETF
3.35%
State Street SPDR S&P Pharmaceuticals ETF
2.51%
AAM Sawgrass US Large Cap Quality Growth ETF
2.47%
Themes US R&D Champions ETF
1.96%
Ver más
ProShares Pet Care ETF
Proporción9.4%
VanEck Pharmaceutical ETF
Proporción9.02%
VanEck Agribusiness ETF
Proporción7.81%
iShares U.S. Pharmaceuticals ETF
Proporción4.26%
Honeytree US Equity ETF
Proporción3.86%
First Trust NASDAQ Pharmaceuticals ETF
Proporción3.58%
Polen Capital Global Growth ETF
Proporción3.35%
State Street SPDR S&P Pharmaceuticals ETF
Proporción2.51%
AAM Sawgrass US Large Cap Quality Growth ETF
Proporción2.47%
Themes US R&D Champions ETF
Proporción1.96%
Dividendos
Un total de
2.56B
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Dec 11, 2025
ZTS.NB Interim Cash Dividend of gross USD 0.53 paid on Mar 03, 2026 going ex on Jan 20, 2026
Jan 20, 2026
Mar 03, 2026
Jan 20, 2026
Oct 09, 2025
ZTS.NB Final Cash Dividend of gross USD 0.5 paid on Dec 02, 2025 going ex on Oct 31, 2025
Oct 31, 2025
Dec 02, 2025
Oct 31, 2025
May 21, 2025
ZTS.NB Interim Cash Dividend of gross USD 0.5 paid on Sep 03, 2025 going ex on Jul 18, 2025
Jul 18, 2025
Sep 03, 2025
Jul 18, 2025
Feb 06, 2025
ZTS.NB Interim Cash Dividend of gross USD 0.5 paid on Jun 03, 2025 going ex on Apr 21, 2025
Apr 21, 2025
Jun 03, 2025
Apr 21, 2025
Dec 12, 2024
ZTS.NB Interim Cash Dividend of gross USD 0.5 paid on Mar 04, 2025 going ex on Jan 21, 2025
Jan 21, 2025
Mar 04, 2025
Jan 21, 2025
Oct 10, 2024
ZTS.NB Final Cash Dividend of gross USD 0.432 paid on Dec 03, 2024 going ex on Oct 31, 2024
Oct 31, 2024
Dec 03, 2024
Oct 31, 2024
May 22, 2024
ZTS.NB Interim Cash Dividend of gross USD 0.432 paid on Sep 04, 2024 going ex on Jul 18, 2024
Jul 18, 2024
Sep 04, 2024
Jul 18, 2024
Feb 06, 2024
ZTS.NB Interim Cash Dividend of gross USD 0.432 paid on Jun 04, 2024 going ex on Apr 18, 2024
Apr 19, 2024
Jun 04, 2024
Apr 18, 2024
Dec 07, 2023
ZTS.NB Interim Cash Dividend of gross USD 0.432 paid on Mar 01, 2024 going ex on Jan 18, 2024
Jan 19, 2024
Mar 01, 2024
Jan 18, 2024
Oct 12, 2023
ZTS.NB Final Cash Dividend of gross USD 0.375 paid on Dec 01, 2023 going ex on Oct 31, 2023
Nov 01, 2023
Dec 01, 2023
Oct 31, 2023
Ver más
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Zoetis Inc?
Los cinco principales accionistas de Zoetis Inc son:
The Vanguard Group, Inc. posee 47.78M acciones, lo que representa el 10.84% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 22.80M acciones, lo que representa el 5.17% del total de acciones.
State Street Investment Management (US) posee 19.65M acciones, lo que representa el 4.46% del total de acciones.
State Farm Insurance Companies posee 16.87M acciones, lo que representa el 3.83% del total de acciones.
Geode Capital Management, L.L.C. posee 11.14M acciones, lo que representa el 2.53% del total de acciones.
The Vanguard Group, Inc. posee 47.78M acciones, lo que representa el 10.84% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 22.80M acciones, lo que representa el 5.17% del total de acciones.
State Street Investment Management (US) posee 19.65M acciones, lo que representa el 4.46% del total de acciones.
State Farm Insurance Companies posee 16.87M acciones, lo que representa el 3.83% del total de acciones.
Geode Capital Management, L.L.C. posee 11.14M acciones, lo que representa el 2.53% del total de acciones.
¿Cuáles son los tres principales tipos de accionista de Zoetis Inc?
Los tres principales tipos de accionista de Zoetis Inc son:
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
¿Cuántas instituciones poseen acciones de Zoetis Inc (ZTS)?
A fecha de 2025Q4, 3273 instituciones poseen acciones de Zoetis Inc, con un valor de mercado combinado de aproximadamente 437.10M, lo que representa el 99.18% del total de acciones. En comparación con el 2025Q3, el accionariado institucional ha aumentado en 0.89%.
¿Cuál es la mayor fuente de ganancias de Zoetis Inc?
El FY2025Q3, el segmento empresarial Parasiticides generó la ganancia más alta para Zoetis Inc, ascendiendo a 564.00M y representando el 23.50% de la ganancia total.
